WO2014151079A8 - Ratio based biomarkers and methods of use thereof for the detection and prognosis of cancer - Google Patents

Ratio based biomarkers and methods of use thereof for the detection and prognosis of cancer Download PDF

Info

Publication number
WO2014151079A8
WO2014151079A8 PCT/US2014/024936 US2014024936W WO2014151079A8 WO 2014151079 A8 WO2014151079 A8 WO 2014151079A8 US 2014024936 W US2014024936 W US 2014024936W WO 2014151079 A8 WO2014151079 A8 WO 2014151079A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer
determination
disease
treatment
Prior art date
Application number
PCT/US2014/024936
Other languages
French (fr)
Other versions
WO2014151079A3 (en
WO2014151079A2 (en
Inventor
Stephen M. Hewitt
Joon-Yong Chung
Udayan GUHA
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,176 external-priority patent/US20130210648A1/en
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority to EP14723537.8A priority Critical patent/EP2972374A2/en
Priority to CA2904973A priority patent/CA2904973A1/en
Publication of WO2014151079A2 publication Critical patent/WO2014151079A2/en
Publication of WO2014151079A3 publication Critical patent/WO2014151079A3/en
Publication of WO2014151079A8 publication Critical patent/WO2014151079A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix

Abstract

Compositions, methods and kits are described for identifying biomolecules (e.g., proteins and nucleic acids) expressed in a biological sample that are associated with the presence, development, or progression of a disease (such as cancer), or more generally determination of the etiology or risk factors associated with a disease. Sample types analyzed by the disclosed methods include but are not limited to archival tissue blocks that have been preserved in a fixative, tissue biopsy samples, tissue microarrays, and so forth. The methods disclosed herein correlate expression profiles of biomolecules with various disease types, and allow for the determination of relative survival rates; in some embodiments, the methods permit determination of survival rates for a subject with cancer. In other embodiments, the disclosure relates to methods for evaluating therapeutic regimes for the treatment, such as treatment of cancer.
PCT/US2014/024936 2013-03-15 2014-03-12 Ratio based biomarkers and methods of use thereof WO2014151079A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP14723537.8A EP2972374A2 (en) 2013-03-15 2014-03-12 Ratio based biomarkers and methods of use thereof
CA2904973A CA2904973A1 (en) 2013-03-15 2014-03-12 Ratio based biomarkers and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/841,176 US20130210648A1 (en) 2009-01-14 2013-03-15 Ratio based biomarkers and methods of use thereof
US13/841,176 2013-03-15

Publications (3)

Publication Number Publication Date
WO2014151079A2 WO2014151079A2 (en) 2014-09-25
WO2014151079A3 WO2014151079A3 (en) 2015-03-05
WO2014151079A8 true WO2014151079A8 (en) 2015-04-30

Family

ID=50693967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/024936 WO2014151079A2 (en) 2013-03-15 2014-03-12 Ratio based biomarkers and methods of use thereof

Country Status (3)

Country Link
EP (1) EP2972374A2 (en)
CA (1) CA2904973A1 (en)
WO (1) WO2014151079A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6115801B2 (en) 2007-03-27 2017-04-19 イミュノヴィア・アーベー Protein signature / marker for adenocarcinoma detection
WO2018201083A1 (en) * 2017-04-28 2018-11-01 University Of Southern California System and method for predicting survival time
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
US6969615B2 (en) 1999-07-26 2005-11-29 20/20 Genesystems, Inc. Methods, devices, arrays and kits for detecting and analyzing biomolecules
AU2002336421A1 (en) 2001-08-31 2003-04-14 The Government Of The United States Of America, Asrepresented By The Secretary Of The Department Of Measurements of multiple molecules using a cryoarray
NZ606687A (en) * 2009-01-14 2014-08-29 Us Health Ratio based biomarkers and methods of use thereof
US20130210648A1 (en) * 2009-01-14 2013-08-15 The United States of America, as Represented by the Secretary, Department of Health and Human Services Ratio based biomarkers and methods of use thereof
JP4782854B2 (en) * 2009-03-10 2011-09-28 ナショナル ヤン−ミン ユニバーシティ Methods for predicting potential metastatic potential, prognosis, or overall survival of cancer patients
KR101918004B1 (en) * 2009-10-26 2018-11-13 애보트 모레큘러 인크. Diagnostic methods for determining prognosis of non-small cell lung cancer
US20120052508A1 (en) * 2010-08-27 2012-03-01 Rutgers, The State University Of New Jersey Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies

Also Published As

Publication number Publication date
WO2014151079A3 (en) 2015-03-05
CA2904973A1 (en) 2014-09-25
WO2014151079A2 (en) 2014-09-25
EP2972374A2 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
WO2010083252A3 (en) Ratio based biomarkers and methods of use thereof
WO2013033629A3 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
JO3812B1 (en) Antibodies that bind to human programmed death ligand 1 (pd-l1)
MX2016016904A (en) Analysis of nucleic acid sequences.
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
WO2014151764A3 (en) Methods and compositions for classification of samples
WO2014140933A8 (en) Method for the prognosis and treatment of cancer metastasis
WO2014170497A3 (en) Method for identifying the quantitative cellular composition in a biological sample
WO2008154098A3 (en) Reagents and methods for mirna expression analysis and identification of cancer biomarkers
WO2012177945A3 (en) Diagnostic methods for eosinophilic esophagitis
WO2012031008A3 (en) Cancer-related biological materials in microvesicles
WO2011119934A3 (en) Methods and materials for detecting colorectal neoplasm
NZ621733A (en) Lung cancer biomarkers and uses thereof
NZ609824A (en) Immunochromatography devices, methods and kits
EP3159695A3 (en) Methods for diagnosing pancreatic cancer
WO2015193325A3 (en) Ceramides and their use in diagnosing cvd
WO2016127077A3 (en) Systems and methods for detection and analysis of biological species
WO2018081625A3 (en) Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
WO2013166444A3 (en) Biomarker analysis using scodaphoresis
EP3135774A3 (en) Complex sets of mirnas as non-invasive biomarkers for kidney cancer
MX2020006728A (en) Methods for measuring analyte and/or protein in biological samples.
WO2015054700A3 (en) Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof
MY193895A (en) Combination test for colorectal cancer
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
EP3736571A4 (en) Method, reagent, and chip, for measuring analyte concentration in biological sample

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14723537

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2014723537

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2904973

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE